McDermott Will & Schulte has advised Applied DNA Sciences. Ellenoff, Grossman & Schole has advised Lucid Capital Markets. Ruskin Moscou Faltischek has advised Cypress Management. Applied...
Applied DNA Sciences Closes $27 Million PIPE Financing and Shifts to Digital Asset Treasury Focus
Applied DNA Sciences’ $12 Million Public Offering
McDermott Will & Emery represented Applied DNA Sciences, Inc. on the offering. Applied DNA Sciences, Inc. (Applied DNA), a leader in PCR-based DNA technologies, executed its...
Inhibikase Therapeutics’ $4 Million Common Stock Offering
McDermott Will & Emery represented Inhibikase Therapeutics in the transaction. Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the...
Applied DNA Sciences’ $3.44 Million Shares Offering
McDermott Will & Emery represented Applied DNA Sciences, Inc., while Harter Secrest & Emery represented the placement agent in the transaction. Applied DNA Sciences, Inc. (Applied...
Applied DNA’s Acquisition of Spindle Biotech
McDermott represented Applied DNA Sciences, Inc. in the transaction. Applied DNA Sciences, Inc. (“Applied DNA”), a leader in PCR-based DNA technologies, announced its acquisition of Spindle...
Inhibikase Therapeutics’ $10 Million Direct Offering and Private Placements
McDermott Will & Emery represented Inhibikase Therapeutics, Inc. in the transaction. Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the...
Spine Biopharma’s $13 Million Series B Equity Financing
McDermott Will & Emery represented Spine Biopharma in the transaction. Spine Biopharma, Inc, a biopharmaceutical company committed to developing non-opiate, non-surgical therapies for the treatment of...
PharmaCyte Biotech’s $15 Million Follow-On Public Offering
Troutman Pepper Hamilton Sanders advised PharmaCyte Biotech, Inc. on the deal. PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer...
PharmaCyte’s $70 Million Rights Offering
Troutman Pepper Hamilton Sanders advised PharmaCyte Biotech on the deal. PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and...
BioXcel Therapeutics’ $100 Million Public Offering
Troutman Pepper Hamilton Sanders LLP advised BioXcel LLC on the deal. BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, announced the pricing of an...
Inhibikase Therapeutics’ $45 Million Follow-On Public Offering
Troutman Pepper Hamilton Sanders LLP advised Inhibikase Therapeutics, Inc. on the deal. Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the...
Pacira Biosciences’ $3M Investment in Spine BioPharma
Troutman Pepper Hamilton Sanders LLP advised Spine BioPharma, LLC on the deal. Spine BioPharma, LLC, a company committed to developing non-surgical, non-opiate therapies to treat degenerative...